Built from the Biology Up.
MISSION
Feromics is the first and only AI-driven functional immunomics platform built from the biology up — where function is the foundation and AI is the engine that scales it. By isolating disease-specific immune cells and measuring the functional pathways that drive disease and therapeutic response, we accelerate new treatments for cancer and autoimmune diseases — translating functional discoveries into validated targets, therapeutic candidates, and actionable intelligence that partners can move directly into the clinic.
Feromics was built on a single belief: that measuring immune cell function — directly, precisely, at single-cell resolution — is the key to unlocking the next generation of immunotherapy.
Feromics was built on a single belief: that measuring immune cell function — directly, precisely, at single-cell resolution — is the key to unlocking the next generation of immunotherapy.
ABOUT
Feromics applies its Intelligent Design™ platform to some of the most consequential unsolved problems in immunotherapy — identifying the functional pathways that regulate immune cytotoxicity in cancer, characterizing the pathogenic cell programs driving autoimmune disease, and generating the function-labeled data that AI models need to produce reliable, clinically actionable predictions. Our team of scientists, engineers, and clinicians brings deep expertise across immunology, single-cell biology, bioinformatics, and clinical development — united by a single conviction that biology, measured at the level of function, is the key to better medicine
.
Approach
PRECISION. PERSONALIZATION. INNOVATION.
Feromics' approach begins with function — the direct, real-time observation of what individual immune cells do in the context of a specific disease. This starting point changes everything. Cells selected for their functional relevance produce molecular data that is cleaner, more specific, and more meaningful than data collected without functional context. The biology itself is superior — and superior biology produces superior AI.
This function-first workflow produces proprietary libraries of interacting disease and immune cells — categorized by functional phenotypes including cancer cell-killing, pathogenic cell depletion, serial killing, and exhaustion. These libraries feed directly into AI models that learn from verified functional outcomes rather than molecular correlations alone — producing predictions that are grounded in what cells actually do, and informing the design of CAR-T, CAR-Treg, and engager-based therapies with a level of biological specificity no standard dataset can match.
Donor Intelligence extends this capability into cell therapy manufacturing — identifying and selecting high-performance donors based on verified functional killing data, ensuring the cells going into development are the cells most likely to produce durable clinical outcomes. Every step, from functional selection to clinical prediction, is driven by the same conviction: biology first, always.
Partnerships
FUNCTIONAL INTELLIGENCE
FOR IMMUNOLOGY PARTNERS
Feromics delivers functional intelligence at every stage of drug development — from target validation and donor selection to patient stratification and companion diagnostic development. Powered by our Intelligent Design™ platform, every partnership is built on the same foundation: verified functional biology that produces better models, better predictions, and better medicine.
We work with:
-
Pharmaceutical companies
-
Biotech organizations
-
AI and technology companies
-
Cell therapy manufacturers
-
Clinical developers
-
Academic medical centers and research institutions
Grants
SUPPORTING OUR RESEARCH
Feromics was awarded a $4.1M, three-year contract from the Advanced Research Projects Agency for Health (ARPA-H) to develop a precision medicine technology that improves patient treatment selection in cancer immunotherapy.
Under Contract No. 75N91024C00036, ARPA-H — part of the Department of Health and Human Services — independently validates Feromics' platform and approach as a breakthrough precision medicine technology.
Feromics is also the recipient of the Sanofi IDEA Award, recognizing the platform as an innovation partner to one of the world's leading pharmaceutical companies.
OUR STORY
Feromics began at the laboratory of Associate Professor Tania Konry at Northeastern University, where engineers, biologists, and computer scientists developed a novel biotechnology for single-cell assays in cancer and autoimmune disease. Her work has produced numerous scientific papers and patents, alongside collaborations with leading pharmaceutical companies.
In 2022, Dr. Shai Schubert — an accomplished biotech founder with a PhD from the Technion and postdoctoral training at the Harvard-MIT Program in Health Sciences and Technology — joined Dr. Konry as CEO to co-found Feromics, bringing the commercial vision and operational expertise to transform a decade of groundbreaking academic research into a platform company with a single mission: translating functional biology into the next generation of immunotherapy.
The scientific foundation of Feromics' Intelligent Design™ platform has been independently validated by the U.S. government — and Feromics was awarded a $4.1 million grant from ARPA-H, the Advanced Research Projects Agency for Health, in recognition of its potential to transform cancer immunotherapy.
From immune behavior to AI intelligence, descriptive biology to predictive medicine, trial-and-error to rational design—Feromics is advancing the standard in immuno-oncology.